Sobi - Swedish Orphan Biovitrum AB (publ) in den Nachrichten
Zugang zu Therapien für seltene Krankheiten
Tamtam hat 20 aktuelle Artikel über Sobi - Swedish Orphan Biovitrum AB (publ) gefunden.
- Swedish Orphan Biovitrum AB (publ) (SOBI.ST) stock price, news, quote and history
- Swedish Orphan Biovitrum AB (publ) (SOBI.ST) stock price, news, quote and history
- Swedish Orphan Biovitrum AB (publ) (OMXSTO:SOBI) Pays $75M As Innate Deal Becomes Effective
- Sobi and Innate announce partnership is now effective following completion of closing conditions
- Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome
- Sobi has completed an issue of class C shares
- Sobi has completed an issue of class C shares
- Sobi has completed an issue of class C shares
- Sobi has completed an issue of class C shares
- Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
- Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
- Lacutamab Moves Toward Planned Phase 3 Trial in Rare T-Cell Lymphoma
- Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
- The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under an incentive programme
- Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
- Have Insiders Sold Swedish Orphan Biovitrum Shares Recently?
- Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
- Have Insiders Sold Swedish Orphan Biovitrum Shares Recently?
- Guido Oelkers to step down as CEO of Sobi in the beginning of 2027
- Guido Oelkers to step down as CEO of Sobi in the beginning of 2027
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie Sobi - Swedish Orphan Biovitrum AB (publ)?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden